Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
South Korean Won: Semiconductor risk and inflation dynamics – BNY

South Korean Won: Semiconductor risk and inflation dynamics – BNY

FXStreetFXStreet2026/07/02 21:12
By:FXStreet

BNY’s report underscores heavy selling in South Korean semiconductor stocks and warns, via the OECD’s 2026 survey, that Korea’s reliance on chip exports heightens exposure to global tech-cycle swings. The OECD urges fiscal support for domestic demand near term and consolidation later, while South Korea’s CPI shows modest firming with mixed sector moves and stable core inflation, keeping energy volatility in focus.

Korea tech dependence and price pressures

"Heavy selling in semiconductor stocks hit markets across South Korea, Japan and Taiwan as investors questioned whether the scale of AI-related capital spending can continue to justify recent gains, while Chinese tech indices also suffered sharp losses."

"The move came as the OECD warned that South Korea’s growing dependence on semiconductor exports is increasing the economy’s exposure to swings in the global technology cycle, reinforcing concerns around concentration risk."

"The OECD’s 2026 Economic Survey of Korea has warned that South Korea’s heavy reliance on semiconductor exports, while a key growth driver, is increasing exposure to external shocks, output volatility and tax revenue swings. It noted that export and investment growth accelerated in early 2026, supported by the AI boom, but said this dependence is also creating strategic vulnerabilities."

"The report urged the government to use fiscal policy to support domestic demand in the near term, while consolidating over the medium term to preserve fiscal health amid rapidly rising aging-related spending pressures. It also called for a stronger fiscal framework, later pension eligibility, labor market reform and broader tax reform, especially in property taxation."

"South Korea’s consumer price index rose 0.1% m/m and 3.2% y/y in June, accelerating from 0.5% m/m and 3.1% y/y in May. The core index excluding food and energy was unchanged m/m and up 2.5% y/y, in line with the previous month.Price pressures were led by furnishings, household equipment and routine maintenance (+1.2% m/m), food and non-alcoholic beverages (+0.4%), alcoholic beverages and tobacco (+0.3%) and health (+0.2%)."

(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales